​

Funding Round

Series D - Cambridge Epigenetix

Series D - Cambridge Epigenetix

Investment Firm

Overview

Cambridge Epigenetix is using epigenetics to reduce several routine & important diagnostic tests for common cancers to a simple blood draw.

Announced Date

Nov 02, 2021

Funding Type

Series D

Highlights

Location

Europe

Social

Investor Lead

Temasek Holdings

Temasek Holdings

Temasek Holdings is a early_stage_venture and late_stage_venture and private_equity and secondary_market firm.

Participant Investors

4

Investor Name
Participant InvestorTemasek Holdings
Participant InvestorNew Science Ventures
Participant InvestorGoogle Ventures
Participant InvestorSequoia Capital

Round Details and Background

Cambridge Epigenetix raised $88000000 on 2021-11-02 in Series D

Cambridge Epigenetix is using epigenetics to reduce several routine & important diagnostic tests for common cancers to a simple blood draw.

Company Funding History

5

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Nov 24, 2020
Convertible Note - Cambridge Epigenetix
-10.7M
Nov 02, 2021
Series D - Cambridge Epigenetix
6-88.0M
Mar 14, 2016
Series B - Cambridge Epigenetix
5-21.0M
Oct 29, 2014
Series A - Cambridge Epigenetix
3-5.5M

Recent Activity

There is no recent news or activity for this profile.